Skip to content

Cohort study, 2023

Do women with premenstrual disorders go through menopause earlier and have worse hot flashes?

Yes. Women with premenstrual disorders went into menopause about 2.67 times earlier and were more likely to have moderate or severe hot flashes (68.3% versus 55.3%).

Strong study design 1,220 US nurses with premenstrual disorders and 2,415 without, median age about 40-41 years

What they did

Prospective cohort study of US nurses. Researchers followed 1,220 women with premenstrual disorders and 2,415 without for a median of 20.3 years. They assessed when menopause occurred and how severe hot flashes were.

What they found

Women with premenstrual disorders reached menopause earlier (7.1 per 1000 person-years versus 2.7 per 1000 person-years, hazard ratio 2.67). 68.3% of women with premenstrual disorders had moderate or severe hot flashes compared to 55.3% without (odds ratio 1.68). There was no difference in mild hot flashes.

What it means for you

Premenstrual disorders may be linked to body changes that lead to earlier menopause and worse hot flashes. This could help doctors identify women at risk of earlier menopause. A main limitation is this study only included US nurses, so results may not apply to all women.

2.67

hazard ratio for early menopause with premenstrual disorders

68.3%

had moderate or severe hot flashes with premenstrual disorders

20.3 years

median follow-up

About the study

Original title
Premenstrual Disorders, Timing of Menopause, and Severity of Vasomotor Symptoms
Authors
Yang Y, Valdimarsdóttir UA, Manson JE et al.
Journal
JAMA network open
Year
2023
Study design
Cohort study
Participants
2,415
What was tested
None - this was an observational study
Open access
Yes
Original abstract

Importance: Although premenstrual disorders (PMDs) end at menopause, it is unclear whether they are associated with the timing and symptom severity of menopause. Objective: To prospectively examine whether women with PMDs have increased risks of early menopause and menopause-related vasomotor symptoms (VMS). Design, setting, and participants: This population-based cohort study was nested in the Nurses' Health Study II (data collected from questionnaire sent between June 1991 and June 2017). Analysis of menopause timing included participants who did not have natural or surgical menopause before study entry, while the analysis of VMS was restricted to women who provided information on VMS. Data were analyzed from August 2022 to March 2023. Exposures: PMDs were identified by self-reported diagnosis and confirmed with symptom questionnaires from 1991 to 2005. Participants were age-matched to women without PMD diagnoses and confirmed absence of or minimal premenstrual symptoms. Main outcomes and measures: During follow-up through 2017, timing of natural menopause was assessed biennially, and VMS were assessed in 2009, 2013, and 2017. The association of PMDs with early menopause was assessed by Cox proportional hazards models and with VMS by logistic regression models. Results: Of 1220 included women with PMDs, the median (IQR) age was 40.7 (37.3-43.8) years; of 2415 included women without PMDs, the median (IQR) age was 41.7 (38.3-44.8) years. The median (IQR) follow-up in this study was 20.3 (17.8-22-2) years. Early natural menopause (menopause before age 45 years) was reported by 17 women with PMDs (7.1 per 1000 person-years) and 12 women without PMDs (2.7 per 1000 person-years; adjusted hazard ratio, 2.67; 95% CI, 1.27-5.59). In addition, 795 women with PMDs (68.3%) and 1313 women without PMDs (55.3%) reported moderate or severe VMS (adjusted odds ratio, 1.68; 95% CI, 1.32-2.14). There was no observed association between PMDs and mild VMS (adjusted odds ratio, 0.99; 95% CI, 0.76-1.28). Conclusions and relevance: In this cohort study of US women, PMDs were associated with increased risks of early menopause and moderate or severe VMS. PMDs may be indicative of underlying physiology linked to early menopause and VMS, suggesting a phenotype observable during the reproductive years that may allow clinicians to target women at risk of earlier menopause and subsequent health risks later in the life course.

Reproduced under CC-BY.

Topics